M&A and Regulatory Compliance

Movano Inc.'s all-stock merger with Corvex carries a medium probability of regulatory delay or rejection by SEC, FTC, or antitrust authorities. The healthcare technology transaction could face unfavorable conditions that alter deal economics. Nasdaq-listed Movano confronts a catastrophic-severity regulatory risk as authorities scrutinize the combination.